Lifecore Biomedical to Participate at CPHI Global Conference
Lifecore plans customer meetings on injectable CDMO services at the CPHI Global Conference in Milan in October 2026.
Rhea-AI Summary
Lifecore Biomedical (LFCR) will participate in the CPHI Global Conference taking place October 6-8, 2026, in Milan, Italy.
Company leaders, including chief commercial officer Mark DaFonseca and business development directors Mary Evelyn Hudson, Edward Purell, and Dan Dennehy, will host meetings with prospective customers to discuss process development and manufacturing services for injectable programs at booth 8J60. Interested parties are invited to schedule meetings via the provided CDMO email contact.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Sep 02 | Commercial site transfer | Positive | +8.0% | Added a late-stage commercial program to Lifecore's CDMO pipeline. |
| Aug 05 | Q2 earnings report | Negative | +2.1% | Revenue declined and net loss widened, despite reaffirmed full-year guidance. |
| Jul 29 | Q2 reporting notice | Neutral | +0.9% | Announced the August 5 release date for second-quarter financial results. |
| Jul 28 | Customer agreements | Positive | +1.1% | Signed three agreements expanding early- and late-stage CDMO programs. |
| Jul 15 | Inducement grant | Negative | +1.9% | Granted restricted stock units covering 3,500 common shares to a new employee. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent announcements generally preceded positive price reactions, including mixed earnings results and an inducement grant.
Key Terms
cdmo financial
fill and finish technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CHASKA, Minn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the CPHI Global Conference. The conference will take place October 6-8, 2026, in Milan, Italy.
Details regarding Lifecore’s participation are as follows:
- CPHI Global Conference
Details: Lifecore leaders, including Mark DaFonseca, chief commercial officer, and business development directors Mary Evelyn Hudson, Edward Purell, and Dan Dennehy, will host meetings with prospective customers to discuss process development and manufacturing services for injectable programs.
Booth number: 8J60
Conference Dates: October 6-8, 2026
Location: Fiera Milano, Italy
If you are interested in meeting with Lifecore during this event, please reach out to us at: cdmo@lifecore.com.
About Lifecore Biomedical
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.
Contact Information:
Vida Strategic Partners
Stephanie Diaz (Investors)
415-675-7401
sdiaz@vidasp.com
Jennifer Arcure (Media)
917-603-0681
jarcure@vidasp.com
Lifecore Biomedical
Ryan D. Lake (CFO)
952-368-6244
ryan.lake@lifecore.com
